Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Life-Cycle Management Heads To Court; Abbott Faces Antitrust Trial On Tricor

Executive Summary

A Delaware federal court will decide whether innovator firms' strategy of making minor changes to a product late in patent life, thereby blocking generic competition, is anticompetitive

You may also be interested in...



Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding

New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.

States Sue Abbott Over Its “Scheme” To Block Generic TriCor Competition

Eighteen states and the District of Columbia filed an antitrust suit against Abbott and its marketing partner Fournier claiming they illegally blocked generic competition for TriCor (fenofibrate) by making minor changes in the drug's formulation and filing baseless patent infringement suits

States Sue Abbott Over Its “Scheme” To Block Generic TriCor Competition

Eighteen states and the District of Columbia filed an antitrust suit against Abbott and its marketing partner Fournier claiming they illegally blocked generic competition for TriCor (fenofibrate) by making minor changes in the drug's formulation and filing baseless patent infringement suits

Latest News
See All
UsernamePublicRestriction

Register

PS047243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel